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Ablation and Progression of Atrial Fibrillation. Objective: The objective was to determine the effect of
radiofrequency catheter ablation (RFA) on progression of paroxysmal atrial fibrillation (AF).
Background: Progression to persistent AF may occur in up to 50% of patients with paroxysmal AF
receiving pharmacological therapy. Hypertension, age, prior transient ischemic event, chronic obstructive
pulmonary disease, and heart failure (HATCH score) have been identified as independent risk factors for
progression of AF.
Methods: RFA was performed in 504 patients (mean age: 58 ± 10 years) to eliminate paroxysmal AF. A
repeat RFA procedure was performed in 193 patients (38%). Clinical variables predictive of outcome and
their relation to progression of AF after RFA were assessed using multivariate analysis.
Results: At a mean follow-up of 27 ± 12 months after RFA, 434/504 patients (86%) were in sinus rhythm;
49/504 patients (9.5%) continued to have paroxysmal AF; and 14 (3%) were in atrial flutter. Among the
504 patients, 7 (1.5%) progressed to persistent AF. In patients with recurrent AF after RFA, paroxysmal
AF progressed to persistent AF in 7/56 (13%, P < 0.001). The progression rate of AF was 0.6% per
year after RFA (P < 0.001 compared to 9% per year reported in pharmacologically treated patients).
Age >75 years, duration of AF >10 years and diabetes were independent predictors of progression to
persistent AF. The HATCH score was not significantly different between patients with paroxysmal AF who
did and did not progress to persistent AF (0.7 ± 0.8 vs 1.0 ± 0.5, P = 0.3).
Conclusions: Compared to a historical control group of pharmacologically treated patients with parox-
ysmal AF, RFA appears to reduce the rate of progression of paroxysmal AF to persistent AF. Age, duration
of AF, and diabetes are independent risk factors for progression to persistent AF after RFA. (J Cardiovasc
Electrophysiol, Vol. 23, pp. 9-14, January 2012)
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Introduction
Earlier studies have demonstrated that atrial fibrillation
(AF) may progress from paroxysmal to persistent in up
to 50% of patients despite pharmacologic therapy.1-3 Heart
failure, advanced age, prior cerebrovascular events, chronic
obstructive pulmonary disease (COPD), and hypertension
(HATCH score) have been reported as independent predictors
of progression of AF in pharmacologically treated patients.2
However, it is not clear whether radiofrequency catheter ab-
lation (RFA) can prevent progression of paroxysmal AF, and
whether HATCH parameters would still be predictive of pro-
gression after RFA of AF. Thus, the purpose of this study was
to systematically assess the role of RFA on progression of
Supported in part by a grant from the Leducq Transatlantic Network
Dr. Oral is a consultant and/or advisory board member of Medtronic-
Ablation Frontiers. Other authors: No disclosures.
Address for correspondence: Krit Jongnarangsin, M.D., University of Michi-
gan Cardiovascular Center, 1500 East Medical Center Dr., Ann Arbor, MI
48109-5853, USA. Fax: +734-214-0691; E-mail: kritj@umich.edu
Manuscript received 6 December 2010; Revised manuscript received 19
May 2011; Accepted for publication 31 May 2011.
doi: 10.1111/j.1540-8167.2011.02137.x
AF in patients with paroxysmal AF and to identify predictors
of progression to persistent AF after RFA.
Methods
Study Subjects
A total of 525 consecutive patients with paroxysmal AF
who underwent RFA to eliminate AF between January 1,
2006 and December 31, 2008 were enrolled in this study.
Despite rigorous efforts, current rhythm status could not
be confirmed in 21 patients. Adequate data for analysis
were available in 504 of the 525 patients (96%) included in
the study. Clinical characteristics and the HATCH score of
the patients lost to follow-up and included in the analysis
were similar.
Among the 504 patients, there were 338 men and 166
women, and their mean age was 58 ± 10 years. The mean
left ventricular ejection fraction and left atrial diameter were
0.58 ± 0.07 and 41 ± 6 mm, respectively. AF was first
diagnosed 69 ± 67 months prior to presentation (Table 1).
Patients who underwent a prior catheter or surgical ablation
procedure for AF were excluded from this study.
Electrophysiologic Study and Radiofrequency Ablation
The study protocol was approved by the Institutional
Review Board. An electrophysiologic study and RFA was
performed in the fasting state under conscious sedation. All
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antiarrhythmic drugs except amiodarone were discontinued
at least 4–5 half-lives before the study. Amiodarone was
discontinued 8 weeks earlier. Vascular access was obtained
through a femoral vein. A multipolar electrode catheter po-
sitioned in the coronary sinus was used for recording elec-
trograms and atrial pacing. After transseptal puncture, sys-
temic anticoagulation was achieved with intravenous heparin
to maintain an activated clotting time of 325–350 seconds.
All pulmonary veins (PVs) were mapped with a decapolar
ring catheter (Lasso, Biosense Webster, Diamond Bar, CA,
USA). An open irrigation, 3.5 mm tip deflectable tip catheter
(Thermocool, Biosense Webster) was used for mapping and
ablation. Bipolar electrograms were recorded at a band-pass
of 30–500 Hz (EPMed Systems, West Berlin, NJ, USA). An
electroanatomical mapping system (Carto, Biosense Web-
ster) was used to reconstruct the 3-dimensional geometry of
the left atrium and PVs.
Radiofrequency energy was delivered at a maximum
power output of 35 W at a flow rate of 30 mL/min and a
maximum temperature of 48 ◦C. The power was reduced to
20–25 W at a flow rate of 17 mL/min, during applications of
energy near the PV ostia, in the posterior left atrium, or in the
coronary sinus. Antral pulmonary vein isolation (APVI) was
performed in all patients and complete electrical isolation
was confirmed with a circular multipolar catheter. Ablation
of complex fractionated atrial electrograms (CFAEs) and lin-
ear ablation were performed at the discretion of the operator.
Postablation Management and Follow-Up
After an overnight hospital stay with electrocardiographic
monitoring, all patients were discharged home the next day.
All patients were maintained on warfarin ≥3 months after
the RFA. When warfarin was discontinued prior to ablation,
low molecular weight heparin was used to bridge until the
INR was >2.0 after the RFA. The same drug regimen was
continued for 8–12 weeks after ablation in patients who were
receiving an antiarrhythmic drug before the procedure.
Patients were seen for the follow-up at 3, 6, and 12 months
after the ablation procedure. If patients did not have recur-
rence of AF, they would be contacted by phone or mail once
a year for the follow-up. Patients were also asked to call a
clinical coordinator if they experienced symptoms suggestive
of an arrhythmia. The patients were provided with a 30-day
autotrigger event monitor 6 months after ablation and when-
ever they had symptoms. Rhythm monitoring using an event
monitor successfully completed in 80% of the patients. In the
remaining patients data were derived from Holter monitors
or serial electrocardiograms. The mean duration of follow-up
was 25 ± 12 months after the most recent RFA.
A repeat ablation procedure was offered to all patients
with recurrent atrial arrhythmias. During repeat ablation,
APVI was confirmed and repeated as necessary in all patients.
At the discretion of the operator, CFAEs were also targeted
and eliminated and/or linear ablation was performed.
Warfarin was discontinued in patients who were con-
firmed to be in sinus rhythm beyond 3 months after the final
ablation procedure if there was no history of thromboem-
bolic events or another indication to continue anticoagulant
therapy.
Progression of AF
Progression to persistent AF was defined as paroxysmal
AF prior to RFA that became persistent after the RFA. As
stated in the Heart Rhythm Society consensus statement,
persistent AF was defined as an episode of AF that per-
sisted >7 days or required cardioversion.4 Patients who were
free from recurrent AF (with or without concomitant antiar-
rhythmic drug therapy) and patients who continued to have
paroxysmal AF were considered to have remained free from
progression of AF. Patients who had recurrent atrial flut-
ter were not considered to have progression of AF, as atrial
flutter is often a manifestation of proarrhythmia secondary
to prior ablation lesions and not a natural progression of
AF. The HATCH score was determined for each patient.2
The HATCH acronym stands for hypertension (1 point),
age ≥75 years (1 point), transient ischemic attack or stroke
(2 points), COPD (1 point), and heart failure (2 points).
Statistical Analysis
Continuous variables were expressed as mean ± SD.
Baseline characteristics between patients with and without
progression from paroxysmal to persistent AF were com-
pared using Student’s t-test for continuous variables and
Fisher’s exact test for categorical variables. Duration of AF
was compared using the Wilcoxon signed-rank test because
data were not normally distributed. Logistic regression anal-
ysis was used to evaluate independent predictors for pro-
gression to persistent AF. Variables included in the logistic
regression model were selected from baseline characteris-
tics with a P ≤ 0.1 in the univariate analysis. Forward and
backward stepwise methods were used to develop the mul-
tivariate model. All variables included in the model were
tested for interaction. Data analysis was performed with
SAS statistical software (version 9.1, SAS Institute Inc.,
Cary, NC, USA). A two-sided P < 0.05 indicated statistical
significance.
Results
Clinical Outcome after RFA
During a mean follow-up of 27 ± 12 months after the
first RFA, 279 of 504 patients (55%) were in sinus rhythm
including 44 of 504 patients (9%) who were receiving an
antiarrhythmic drug (7 patients on amiodarone). Among the
504 patients, 179 patients (36%) had recurrent AF, 25 (5%)
had atrial flutter, and 21 (4%) had both AF and flutter. A total
of 193 patients (38%) underwent ≥2 RFA procedures: 2
procedures in 165, 3 procedures in 22, 4 procedures in 5, and
5 procedures in 1 patient. A mean of 1.5 ± 0.6 procedures
was performed per patient.
At 22 ± 13 months after the most recent procedure,
434 patients (86%) remained in sinus rhythm, 49 patients
(9.5%) continued to have paroxysmal AF, 7 patients (1.5%)
had persistent AF, and 14 patients (3%) had persistent atrial
flutter. Sixty-five of 434 patients (15%) in sinus rhythm and
13 of 49 patients (27%) with paroxysmal AF were being
treated with an antiarrhythmic drug.
Progression to Persistent AF
Among the 504 patients in this study, AF progressed to
persistent in 7 patients (1.5%) after RFA. Progression to
persistent AF occurred in 7 of the 56 patients (13%) in whom
RFA was not effective in eliminating paroxysmal AF (P <
0.001).
The incidence of AF progression after RFA was 0.6% per
year (Fig. 1). In comparison, the rate of progression of AF
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Figure 1. Rate of AF progression. The
probability of AF progression was 0.6%
per year after RFA in this study (blue
line) versus 8.6% in the first year with
slow but steady progression to 24.7% in
5 years in patients treated pharmacologi-
cally (red line).3
has been reported as 9% during the first year and 25% after
5 years in pharmacologically treated patients with parox-
ysmal AF (P < 0.01 compared to progression of AF after
RFA).3
Predictors of Progression of AF
On univariate analysis, patients who developed per-
sistent AF were older (71 ± 5 vs 58 ± 10 years,
P < 0.01) and were more likely to have diabetes (43%
vs 11%, P = 0.03) than patients without AF progres-
sion (Table 1). On multivariate logistic regression anal-
ysis, age >75 years (OR = 26, ±95% CI: 4–200,
P < 0.01), AF duration >10 years (OR = 6.8, ±95%
CI: 1.4–33.3, P = 0.02) and diabetes (OR = 8.1, ±95%
CI: 1.5–43.5, P = 0.01) were independent predictors of pro-
gression to persistent AF after RFA (Table 2).
HATCH Score
The mean HATCH score was 0.7 ± 0.8. The mean HATCH
score was similar among patients whose AF progressed (1 ±
0.6) and did not progress to persistent AF (0.7 ± 0.8, P =
0.3). The HATCH score was ≥2 in 53 of 477 patients (11%)
without AF progression and in 1 of 7 patients (14%) with
progression to persistent AF (P = 0.57).
CHADS2 Score
The mean CHADS2 score was 0.8 ± 0.8. The mean
CHADS2 score was higher among patients with progression
to persistent AF (1.4 ± 0.5) than without AF progression
(0.8 ± 0.8, P = 0.04). The CHADS2 score was ≥2 in 78/477
patients (16%) without AF progression and in 3 of 7 patients
(43%) with progression to persistent AF (P = 0.1). Although,
the CHADS2 score was a univariate predictor (OR = 1.93,
95% CI = 1.00–3.72, P = 0.05), on multivariate analysis the
CHADS2 score was not predictive of progression to persis-
tent AF after RFA.
Discussion
Main Findings
This study demonstrates that (1) the rate of progression
of paroxysmal AF to persistent AF is low after RFA; (2) the
HATCH score, previously described to be predictive of AF
progression in pharmacologically treated patients, does not
appear to predict progression of AF after RFA in this study.
However, it should be noted that the mean HATCH score was
low in this study; (3) age, duration of AF, and diabetes are
independent predictors of progression of AF after RFA.
These findings suggest that RFA reduces the rate of pro-
gression of paroxysmal AF compared to historical cohorts
of pharmacologically treated patients. It appears that age,
duration of AF, and diabetes have profibrillatory effects that
promote progression to persistent AF after failed RFA of
paroxysmal AF.
Progression of AF
Progression of AF from paroxysmal to persistent is most
likely due to the development of an electroanatomical sub-
strate capable of perpetuating AF.5-7 A number of variables
have been implicated in structural and electrophysiologic
remodeling of the atria. An increase in the duration and fre-
quency of episodes of AF by itself was demonstrated to
promote remodeling in a goat model of AF.7
Aging is associated with an increase in the prevalence
of AF.8 Fibrosis appears to play a key role in promoting
perpetuation of AF in the aging heart and in patients with
structural heart disease.9 AF per se may also facilitate atrial
fibrosis.9 Atrial fibrosis may result in an increase in nonuni-
form anisotropy and local conduction heterogeneity which
perpetuate AF.10 It is not clear whether other factors such as
a change in the autonomic tone and innervation of the heart
also play a role in age-related progression of AF.
In earlier studies, advanced age, left atrial enlargement,
and cardiomyopathy were reported to be predictors of
AF progression in patients receiving pharmacological ther-
apy.2,3,11,12 Atrial dilatation may promote perpetuation of
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Table 1
Baseline Characteristics
Number AF Progression N = 483 Progression to Persistent AF N = 7 P
Age (years) 58 ± 10 71 ± 5 < 0.01
Gender (male/female) 323/160 4/3 0.7
AF duration (months) 67 ± 63 168 ± 169 0.1
Weight (kg) 92 ± 20 87 ± 19 0.5
BMI (kg/m2) 29 ± 6 30 ± 5 0.7
Hypertension 231 (48%) 5 (71%) 0.3
Coronary artery disease 50 (10%) 1 (14%) 0.5
Diabetes mellitus 52 (11%) 3 (43%) 0.03
COPD 11 (2%) 0 1.0
Thyroid disease 68 (14%) 2 (29%) 0.1
CVA 36 (8%) 0 1.0
Left atrial size (mm) 41 ± 6 42 ± 7 0.6
LV EF 0.58 ± 0.07 0.55 ± 0.08 0.3
HATCH score 0.7 ± 0.8 1 ± 0.6 0.3
CHADS2 score 0.7 ± 0.8 1.4 ± 0.5 0.04
Data are shown as mean±SD. Percentages are shown in parentheses. BMI = body mass index; COPD = chronic obstructive pulmonary
disease; CVA = cerebrovascular event; LV EF; left ventricular ejection fraction.
AF through a variety of mechanisms most notably due to an
ability to accommodate longer and multiple wavelengths of
potential reentrant circuits.10
Radiofrequency Catheter Ablation and Progression of AF
Progression of AF has been reported in up to 50% of pa-
tients with paroxysmal AF receiving pharmacological ther-
apy.1-3 It is not clear how often sinus rhythm was maintained
in these patients as no specific predefined attempt was made
to systematically pursue a rhythm control strategy. However,
based on a number of studies that demonstrated only modest
efficacy of antiarrhythmic drug therapy in maintaining sinus
rhythm, it is unlikely that sinus rhythm was maintained in
the majority of patients even when a rhythm control strategy
was attempted.
RFA has been effective in maintaining sinus rhythm,
particularly in patients with paroxysmal AF. Because RFA
is unlikely to modify the aging process or eliminate elec-
troanatomical abnormalities associated with structural heart
disease, effective maintenance of sinus rhythm may have
been the key factor that reduced the rate of progression of
AF. Furthermore, during RFA of paroxysmal AF, typical tar-
gets are intermittent PV tachycardias and triggers originating
from other thoracic veins. Extensive substrate modification
is usually not performed. Therefore, it appears that early and
effective elimination of primarily PV drivers is sufficient to
decrease the rate of progression of AF despite continued
evolution and progression of an atrial substrate capable of
maintaining sinus rhythm. Of note is that paroxysmal AF
progressed to persistent in 13% of the patients in whom RFA
was not effective in controlling AF in this study, similar to
the progression rate reported in an earlier study of patients
Table 2
Multivariate Predictors of Progression to Persistent AF
OR ± 95% CI P
Age >75 years 26 4–200 <0.01
AF duration ≥10 years 6.8 1.4–33.3 0.02
Diabetes mellitus 8.1 1.5–43.5 0.01
who received pharmacological therapy for rate or rhythm
control.2
Similar to the findings of earlier studies, age was an
independent predictor of AF progression after RFA in this
study.2,3 However, unlike earlier studies, the 2 other inde-
pendent predictors of progression of AF after RFA were the
duration of AF prior to RFA and diabetes. A long duration of
AF has long been recognized to promote electroanatomical
remodeling of the atria and is likely to contribute to perpet-
uation of AF.7 In several studies, longer duration of AF has
been associated with a less favorable clinical outcome after
RFA of AF. Therefore, earlier RFA of AF may be more effec-
tive in preventing progression of AF than a late intervention
after atrial remodeling has already started.
Although diabetes is recognized as a risk factor for throm-
boembolic events, the role of diabetes in the pathophys-
iology of AF has not been well established. An earlier
epidemiologic study suggested a higher risk of AF in patients
with metabolic syndrome.13 In addition to obesity, hyperten-
sion, and low-HDL levels, impaired fasting glucose levels
were also an independent risk factor for AF.13 In another
study, diabetes was one of the predictors of progression of
AF after RFA in selected patients with AF.14 In a transgenic
mouse model, a reduction in phosphoinositide 3-kinase activ-
ity, as frequently observed during impaired glucose tolerance
and insulin resistance, was associated with a higher proba-
bility of developing AF.15 In an in vitro study, hypertonicity,
occurring during hyperglycemic states, was found to increase
the frequency of depolarizations in PV myocytes.16 Diabetes
is also associated with microvascular disease, which could
facilitate atrial fibrosis.17 Furthermore, autonomic dysregula-
tion secondary to diabetes may also play a role in the genesis
AF.
Prior Studies
In an earlier study, the HATCH scoring system was pro-
posed to predict the risk of progression of AF in patients re-
ceiving pharmacological therapy.2 In patients with a HATCH
score of ≥6, AF progressed in ∼50% after 1 year, whereas
the rate of progression was 6% in patients with a HATCH
score of 0. The mean HATCH score was lower and the range
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of HATCH scores was also narrower in this study than in the
earlier report. In this study, RFA reduced the rate of progres-
sion to 1.5% in a cohort of patients whose mean HATCH
score was <2. Unlike in the earlier study, hypertension, prior
cerebrovascular events, chronic obstructive pulmonary dis-
ease, and heart failure were not independent predictors of
progression of AF after RFA in this study. However, in ad-
dition to age, duration of AF and diabetes were independent
predictors.
In the Canadian Registry of Atrial Fibrillation (CARAF)
study, the rate of progression of AF was ∼9% during the
first year and 25% over a 5-year follow-up. Age, cardiomy-
opathy, left atrial dilatation, significant aortic stenosis or
mitral regurgitation, and a slower heart rate at presentation
were independent predictors of progression of AF. However,
the role of RFA or any other active intervention for rhythm
control on the rate of progression was not assessed in that
study.
In another study, selected patients who presented to the
hospital with a first documented episode of AF were fol-
lowed for 5 years.14 Age, heart failure, and diabetes were
identified as predictors of progression. RFA was performed
in only 11 of the 56 patients in the study and there was no
recurrence of AF in any of the 11 patients after ablation. This
study systematically investigated the role of RFA on pro-
gression of AF in 504 consecutive patients who underwent
ablation to eliminate paroxysmal AF. Moreover, the effect
of RFA was also analyzed in the context of recently pro-
posed risk factors for progression of AF in patients treated
pharmacologically.
Limitations
A limitation of this study is that there was no
randomized control group and comparisons were made to
historical cohorts of patients. Another limitation is that pa-
tients referred for RFA may have had fewer comorbidities
than patients treated pharmacologically in earlier studies.
Therefore, the progression rate of AF may have been lower
in this study than reported previously. Nevertheless, when
comparisons were made after adjustment of baseline comor-
bidites and HATCH score, RFA still appeared to reduce the
rate of progression in this study.
Despite our effort to obtain a 30-day autotrigger event
monitor at 6 months after ablation in all patients, there were
some patients who did not receive the event monitor. There-
fore, asymptomatic AF episodes could have been missed in
these patients and the actual recurrence rate of atrial arrhyth-
mias could have been higher.
The confidence intervals of predictors of progression to
persistent to AF are very wide. This diverse range of effect
sizes is probably due to a small number of patients who
progressed to persistent AF.
It would have been helpful to determine the relationship
between residual arrhythmia burden after RFA and rate of
progression of AF. However, arrhythmia burden was not sys-
tematically analyzed in this study.
Clinical Implications
The findings of this study suggest that RFA may substan-
tially reduce the rate of progression of AF and should be
considered early in treatment of patients with AF. Further-
more, patients who are less likely to benefit from a rhythm
control strategy using pharmacological therapy may still ben-
efit from RFA to prevent progression of AF.
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